

# PROVIDER QUICK POINTS

## PROVIDER INFORMATION



September 13, 2023

### **Commercial Pharmacy Benefit Exclusion for Abilify Asimtufii<sup>®</sup>, Adstiladrin<sup>®</sup>, Brixadi<sup>™</sup>, Glydo<sup>®</sup>, lidocaine 2%, Roctavian<sup>™</sup>, and Uzedy<sup>™</sup>**

Effective **September 13, 2023**, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

<b>Drug Names</b>
Abilify Asimtufii <sup>®</sup> (aripiprazole) suspension for intramuscular (IM) injection
Adstiladrin <sup>®</sup> (nadofaragene firadenovec-vncg) suspension for intravesical instillation
Brixadi <sup>™</sup> (buprenorphine) extended-release solution for subcutaneous (SC) injection
Glydo <sup>®</sup> (lidocaine HCl jelly) 2% gel for urethral / mucosal topical administration
lidocaine (lidocaine HCl jelly) 2% gel for urethral / mucosal topical administration
Roctavian <sup>™</sup> (valoctocogene roxaparvovec-rvox) suspension for intravenous (IV) infusion
Uzedy <sup>™</sup> (risperidone) extended-release suspension for subcutaneous (SC) injection

#### **Products Impacted**

These exclusions apply to commercial lines of business.

#### **Questions?**

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.